## Introduction
Henoch-Schönlein purpura nephritis (HSPN), now more precisely termed IgA vasculitis with nephritis (IgAV-N), stands as one of the most significant complications of the most common systemic vasculitis in childhood. While many children with Henoch-Schönlein purpura recover without incident, the onset of nephritis introduces the risk of progressive renal injury, hypertension, and long-term chronic kidney disease. This creates a critical challenge for clinicians: to accurately identify and stratify patients with renal involvement, distinguishing those who will resolve spontaneously from those who require targeted, and sometimes aggressive, intervention to preserve kidney function. This article provides a graduate-level framework for understanding and managing this complex condition by bridging foundational science with clinical application.

Across the following chapters, you will gain a deep, mechanistic understanding of HSPN. The first chapter, "Principles and Mechanisms," deconstructs the disease at a molecular and cellular level, exploring the "multi-hit" hypothesis that drives the immune-mediated glomerular damage. The second chapter, "Applications and Interdisciplinary Connections," translates this scientific knowledge into the realities of clinical practice, detailing the diagnostic process, risk stratification, and evidence-based therapeutic strategies. Finally, "Hands-On Practices" will offer the opportunity to apply these concepts to practical clinical scenarios, reinforcing the decision-making skills essential for expert care. We begin by examining the core immunopathological events that initiate and perpetuate this fascinating and challenging disease.

## Principles and Mechanisms

This chapter elucidates the fundamental principles and pathophysiological mechanisms underlying Henoch-Schönlein purpura nephritis (HSPN). We will deconstruct the disease process, beginning with its clinical classification and its position within a spectrum of related disorders, proceeding to the molecular events that initiate the disease, and culminating in the cellular and tissue-level damage that characterizes its renal manifestations.

### The Disease Spectrum: IgA Vasculitis and IgA Nephropathy

Henoch-Schönlein purpura (HSP) is now more formally termed **Immunoglobulin A Vasculitis (IgAV)**, a name that more accurately reflects its underlying immunopathology. IgAV is a systemic small-vessel vasculitis characterized by the deposition of immune complexes containing Immunoglobulin A (IgA). The diagnosis is principally clinical, guided by a set of internationally recognized criteria.

The 2010 European League Against Rheumatism (EULAR), Pediatric Rheumatology International Trials Organization (PRINTO), and Pediatric Rheumatology European Society (PRES) have established consensus classification criteria for pediatric IgAV. These criteria require the presence of a mandatory feature—**palpable purpura** (not related to thrombocytopenia)—typically with a lower limb predominance. In addition to this hallmark finding, at least one of the following four criteria must be met [@problem_id:5152050]:

1.  **Diffuse abdominal pain**: Often described as colicky, it results from vasculitis of the gastrointestinal tract.
2.  **Arthritis or arthralgia**: Typically involving the large joints of the lower extremities.
3.  **Renal involvement**: Defined as the presence of any hematuria (e.g., more than 5 red blood cells per high-power field) and/or proteinuria (e.g., a urine protein-to-creatinine ratio $\ge 0.3 \, \text{mg/mg}$).
4.  **Histopathology**: A biopsy, typically of a skin lesion, showing leukocytoclastic vasculitis with a predominance of IgA deposition in vessel walls.

It is crucial to note that a biopsy is not mandatory for classification; a diagnosis can often be made confidently based on a constellation of clinical findings. For instance, a child presenting with palpable purpura, arthralgia of the knees, and colicky abdominal pain would meet the criteria for IgAV [@problem_id:5152050]. If this child also exhibits hematuria and proteinuria, they are considered to have **Henoch-Schönlein purpura nephritis (HSPN)**, or more precisely, **IgA vasculitis with nephritis (IgAV-N)**. The diagnosis of nephritis is established by the evidence of glomerular inflammation—namely hematuria and/or proteinuria—and does not require an initial reduction in glomerular filtration rate (GFR) [@problem_id:5152050].

IgAV-N exists on a spectrum of diseases with **primary IgA nephropathy (IgAN)**, historically known as Berger's disease. The core distinction between these two conditions is the extent of organ involvement [@problem_id:5152018]. By definition, IgAN is a kidney-limited disease, classically presenting with recurrent episodes of gross hematuria that are temporally linked to mucosal infections. In contrast, IgAV-N is the renal component of a systemic vasculitis, defined by the presence of the extrarenal manifestations described above [@problem_id:5151945]. While the kidney biopsy findings in IgAV-N and IgAN can be histologically indistinguishable, showing dominant mesangial IgA deposition, the presence of systemic vasculitis—evidenced by palpable purpura, arthralgia, or abdominal pain—firmly places the diagnosis in the category of IgAV [@problem_id:5152018]. Therefore, a definitive differentiation between IgAV-N and IgAN relies on the clinical evaluation of extrarenal features, as the renal pathology alone is not sufficient [@problem_id:5152018].

### The Molecular Pathogenesis: A Multi-Hit Hypothesis

The development of IgAV is best understood through a "multi-hit" model, where a sequence of molecular and immunological events culminates in tissue injury.

#### Hit 1 & 2: Mucosal Triggers and Aberrant IgA1 Glycosylation

The onset of IgAV frequently follows an antecedent event, most commonly an upper respiratory tract infection, but also certain vaccinations or medications [@problem_id:5152042]. These events are thought to act as triggers by stimulating the **mucosal immune system**. A key function of mucosal immunity is the production of IgA, the predominant immunoglobulin at mucosal surfaces.

In genetically susceptible individuals, this immune stimulation leads to the overproduction of a structurally abnormal form of the IgA1 subclass. The human IgA1 molecule is unique for its long, [proline](@entry_id:166601)-rich **hinge region**, located between the first and second constant heavy chain domains ($C_H1$ and $C_H2$). This region contains multiple serine and threonine residues that serve as sites for **O-linked glycosylation** [@problem_id:5152032]. In healthy individuals, these O-glycans are complex structures. However, in patients with IgAV and IgAN, a key defect occurs: incomplete [glycosylation](@entry_id:163537). Specifically, there is a deficiency in the addition of galactose to the core N-acetylgalactosamine (GalNAc) sugar. This results in the formation of **galactose-deficient IgA1 (Gd-IgA1)**. The exposed, terminal GalNAc residues on the Gd-IgA1 hinge region constitute a novel antigenic determinant, or **neoepitope** [@problem_id:5152032].

#### Hit 3 & 4: Autoimmunity and Immune Complex Formation

The Gd-IgA1 neoepitopes are recognized as foreign by the individual's own immune system, breaking B-cell tolerance and leading to the production of **anti-glycan autoantibodies**, which are typically of the IgG or IgA isotype [@problem_id:5151947].

The binding of these autoantibodies to Gd-IgA1 molecules initiates the formation of large, pathogenic **circulating immune complexes (CICs)**. This process is governed by the principles of [multivalency](@entry_id:164084). The Gd-IgA1 molecule, which may be dimeric and possesses multiple abnormal O-glycan epitopes ($m \gt 1$), acts as a multivalent antigen. The binding of a [bivalent antibody](@entry_id:186294) (like IgG, with $f=2$) can cross-link multiple Gd-IgA1 molecules. When the concentrations and binding affinity ($K_d$) are favorable, this [cross-linking](@entry_id:182032) leads to the formation of a large, insoluble lattice-like network [@problem_id:5151947]. These large CICs are poorly cleared from the circulation and have a propensity to deposit in small vessels. Deposition in the glomerular mesangium may be facilitated by specific receptors, such as the **transferrin receptor (CD71)**, which is expressed on mesangial cells and has an affinity for IgA1 [@problem_id:5152042].

### Glomerular Pathology: From Deposition to Destruction

Once deposited in the glomerulus, the Gd-IgA1-containing immune complexes initiate a cascade of inflammatory events that cause kidney damage. The pattern and severity of this damage can be visualized through renal biopsy.

#### The Immunofluorescence Hallmark and Complement Activation

The key diagnostic finding on a kidney biopsy from a patient with IgAV-N is seen with [immunofluorescence](@entry_id:163220) microscopy. The hallmark pattern is the **granular deposition of IgA as the dominant or co-dominant immunoglobulin in the glomerular mesangium** [@problem_id:5151921]. This IgA deposition is almost always accompanied by deposits of **complement component 3 (C3)**. Critically, there is a characteristic **absence or scarcity of C1q**.

This specific "staining signature" provides profound insight into the disease mechanism. C1q is the recognition molecule of the classical complement pathway. Its absence indicates that this pathway is not the primary driver of inflammation. Instead, the presence of C3 signifies [complement activation](@entry_id:197846) via the **alternative pathway** and/or the **[lectin pathway](@entry_id:174287)**. The [lectin pathway](@entry_id:174287) is likely initiated when [mannose-binding lectin](@entry_id:178609) (MBL) recognizes the abnormal glycan structures on the deposited Gd-IgA1 molecules [@problem_id:5152042], [@problem_id:5151947]. This [immunofluorescence](@entry_id:163220) pattern is essential for differential diagnosis, as it distinguishes IgAV-N from conditions like [lupus nephritis](@entry_id:194138) (which typically shows a "full-house" pattern including IgG, IgM, C1q, and C3) and post-infectious glomerulonephritis (which is typically IgG and C3 dominant) [@problem_id:5151921]. While serum complement levels are usually normal in IgAV-N, the C3 deposition in the tissue is clear evidence of local complement activation.

#### Mesangial Injury and Proliferation

The deposition of immune complexes and subsequent [complement activation](@entry_id:197846) triggers an inflammatory response centered on the **mesangial cells**. These resident glomerular cells become activated, in part through signaling pathways like **NF-κB**. Activated mesangial cells adopt a pro-inflammatory phenotype, secreting a host of cytokines and growth factors, including **interleukin-6 (IL-6)**, **platelet-derived growth factor (PDGF)**, and **[transforming growth factor-β](@entry_id:197764) (TGF-β)** [@problem_id:5151974].

These mediators drive glomerular pathology through autocrine and paracrine loops. PDGF is a potent mitogen that stimulates mesangial cell proliferation, leading to **mesangial hypercellularity**. TGF-β is a powerful pro-fibrotic cytokine that stimulates the synthesis of **extracellular matrix (ECM)** proteins like collagen and fibronectin, leading to **mesangial matrix expansion** and, ultimately, [glomerulosclerosis](@entry_id:155306). This proliferation and matrix accumulation physically compresses the glomerular capillary loops, reducing the surface area available for filtration ($A_f$). This directly lowers the **ultrafiltration coefficient ($K_f$)**, a key determinant of GFR, thus causing renal function to decline. The inflammatory milieu also damages the integrity of the glomerular filtration barrier, increasing its permeability and resulting in proteinuria and hematuria [@problem_id:5151974].

#### The Pathway to Severe Injury: Crescent Formation

In its most severe form, IgAV-N can progress to a rapidly progressive glomerulonephritis, the histological hallmark of which is **crescent formation**. Crescents are a sign of severe glomerular injury and are formed through a well-defined sequence of events [@problem_id:5151955], [@problem_id:5151940].

The process begins when the intense inflammatory response, fueled by complement anaphylatoxins (e.g., C5a) that recruit neutrophils and monocytes, extends to the capillary walls. The release of proteases and reactive oxygen species by these leukocytes can cause necrotizing lesions and create physical **breaks in the [glomerular basement membrane](@entry_id:168885) (GBM)** [@problem_id:5151955].

These GBM ruptures allow blood and plasma constituents to leak from the capillary lumen into **Bowman's space**. Among the leaked proteins is fibrinogen. Within Bowman's space, local procoagulant factors convert the soluble fibrinogen into a meshwork of insoluble **fibrin**.

This fibrin network, along with [inflammatory chemokines](@entry_id:181065), acts as a powerful pro-inflammatory scaffold and mitogenic stimulus. It triggers the activation and rapid proliferation of the **parietal epithelial cells (PECs)** that line Bowman's capsule. Infiltrating monocytes, which differentiate into macrophages, also contribute to this process. This extracapillary accumulation of proliferating PECs and macrophages forms a **cellular crescent**, which fills Bowman's space, compresses the glomerular tuft, and severely compromises renal function [@problem_id:5151940]. The presence of crescents on a kidney biopsy is a sign of aggressive disease that often warrants more intensive immunosuppressive therapy.